Prognostic role of pretreatment skeletal muscle index in gastric cancer patients: A meta-analysis.

IF 2.3 4区医学 Q3 ONCOLOGY Pathology & Oncology Research Pub Date : 2023-01-01 DOI:10.3389/pore.2023.1611055

Xiaohong He, Sicheng Zhou, Hongjun Li, Yue Gou, Dan Jia

{"title":"Prognostic role of pretreatment skeletal muscle index in gastric cancer patients: A meta-analysis.","authors":"Xiaohong He, Sicheng Zhou, Hongjun Li, Yue Gou, Dan Jia","doi":"10.3389/pore.2023.1611055","DOIUrl":null,"url":null,"abstract":"Background: The association between pretreatment skeletal muscle index (SMI) and long-term survival of gastric cancer patients remains unclear up to now. The aim of this meta-analysis was to identify the prognostic value of pretreatment SMI in gastric cancer. Methods: The PubMed, EMBASE and Web of Science electronic databases were searched up to 5 June 2022 for relevant studies. The primary outcome was overall survival (OS) and the second outcomes were disease-free survival (DFS) and cancer-specific survival (CSS). The hazard ratios (HRs) and 95% confidence intervals (CIs) were combined to assess the relationship between pretreatment SMI and survival of gastric cancer patients. All statistical analyses were conducted by STATA 15.0 software. Results: A total of 31 retrospective studies involving 12,434 patients were enrolled in this meta-analysis. The pooled results demonstrated that lower pretreatment was significantly associated with poorer OS (HR = 1.53, p < 0.001). Besides, lower pretreatment SMI was also related with worse DFS (HR = 1.39, p < 0.001) and CSS (HR = 1.96, p < 0.001). Conclusion: Pretreatment SMI was significantly associated with prognosis of gastric cancer patients and lower SMI predicted worse survival. However, more prospective high-quality studies are still needed to verify our findings.","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164928/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology & Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/pore.2023.1611055","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The association between pretreatment skeletal muscle index (SMI) and long-term survival of gastric cancer patients remains unclear up to now. The aim of this meta-analysis was to identify the prognostic value of pretreatment SMI in gastric cancer. Methods: The PubMed, EMBASE and Web of Science electronic databases were searched up to 5 June 2022 for relevant studies. The primary outcome was overall survival (OS) and the second outcomes were disease-free survival (DFS) and cancer-specific survival (CSS). The hazard ratios (HRs) and 95% confidence intervals (CIs) were combined to assess the relationship between pretreatment SMI and survival of gastric cancer patients. All statistical analyses were conducted by STATA 15.0 software. Results: A total of 31 retrospective studies involving 12,434 patients were enrolled in this meta-analysis. The pooled results demonstrated that lower pretreatment was significantly associated with poorer OS (HR = 1.53, p < 0.001). Besides, lower pretreatment SMI was also related with worse DFS (HR = 1.39, p < 0.001) and CSS (HR = 1.96, p < 0.001). Conclusion: Pretreatment SMI was significantly associated with prognosis of gastric cancer patients and lower SMI predicted worse survival. However, more prospective high-quality studies are still needed to verify our findings.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

预处理骨骼肌指数在胃癌患者预后中的作用:一项meta分析。

背景:预处理骨骼肌指数(SMI)与胃癌患者长期生存的关系目前尚不清楚。本荟萃分析的目的是确定胃癌前SMI治疗的预后价值。方法:检索截至2022年6月5日的PubMed、EMBASE和Web of Science电子数据库，查找相关研究。主要终点是总生存期(OS)，第二终点是无病生存期(DFS)和癌症特异性生存期(CSS)。采用危险比(hr)和95%置信区间(CIs)相结合的方法评估前SMI与胃癌患者生存的关系。所有统计分析均采用STATA 15.0软件进行。结果:本荟萃分析共纳入31项回顾性研究，涉及12434例患者。合并结果显示，预处理越低，OS越差(HR = 1.53, p < 0.001)。预处理SMI越低，DFS (HR = 1.39, p < 0.001)和CSS越差(HR = 1.96, p < 0.001)。结论:胃癌患者前处理SMI水平与预后有显著相关性，SMI水平越低，生存期越差。然而，仍需要更多的前瞻性高质量研究来验证我们的发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pathology & Oncology Research 医学-病理学

CiteScore

6.30

自引率

0.00%

发文量

134

审稿时长

4-8 weeks

期刊介绍： Pathology & Oncology Research (POR) is an interdisciplinary Journal at the interface of pathology and oncology including the preclinical and translational research, diagnostics and therapy. Furthermore, POR is an international forum for the rapid communication of reviews, original research, critical and topical reports with excellence and novelty. Published quarterly, POR is dedicated to keeping scientists informed of developments on the selected biomedical fields bridging the gap between basic research and clinical medicine. It is a special aim for POR to promote pathological and oncological publishing activity of colleagues in the Central and East European region. The journal will be of interest to pathologists, and a broad range of experimental and clinical oncologists, and related experts. POR is supported by an acknowledged international advisory board and the Arányi Fundation for modern pathology.